×
Cellectar Biosciences EBIT 2010-2024 | CLRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cellectar Biosciences ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Cellectar Biosciences EBIT 2010-2024 | CLRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cellectar Biosciences ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$200B
Stryker (SYK)
$141B
Boston Scientific (BSX)
$128B
Medtronic (MDT)
$113B
EssilorLuxottica (ESLOY)
$112.7B
Lonza Group Ag (LZAGY)
$45.3B
Haleon (HLN)
$43.5B
GE HealthCare Technologies (GEHC)
$40.4B
ResMed (RMD)
$36.5B
Terumo (TRUMY)
$30.3B
Koninklijke Philips (PHG)
$25.9B
Zimmer Biomet Holdings (ZBH)
$21.6B
Baxter (BAX)
$18.4B
Insulet (PODD)
$17.2B
Smith & Nephew SNATS (SNN)
$10.8B
Bio-Rad Laboratories (BIO)
$10.4B
BellRing Brands (BRBR)
$8.9B
Demant (WILYY)
$8.4B
Lantheus Holdings (LNTH)
$6.1B
Haemonetics (HAE)
$4.4B
ICU Medical (ICUI)
$4.4B
TG Therapeutics (TGTX)
$4.3B
Prestige Consumer Healthcare (PBH)
$4B
Envista Holdings (NVST)
$3.7B
Perrigo (PRGO)
$3.7B
Neogen (NEOG)
$3.4B
Agios Pharmaceuticals (AGIO)
$3.1B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.9B
QuidelOrtho (QDEL)
$2.6B